HIV

This article examines the ongoing challenge of rising HIV infections in the United States and its implications for ending the epidemic. Despite over 40 years of scientific and medical advancements—including widespread access to antiretroviral therapy (ART), single-pill regimens, long-acting injectables, and pre-exposure prophylaxis (PrEP)—new HIV infections remain disproportionately high among Black and Latine communities.

This study describes the development and implementation of a comprehensive HIV co-testing initiative across Intermountain Health’s urgent care clinics and emergency departments. The program was designed to standardize HIV screening for patients undergoing evaluation for sexually transmitted infections, addressing historically low HIV testing rates in Utah. Key components included clinician and patient education, electronic health record alerts prompting HIV test orders when appropriate, and a structured link-to-care system to ensure rapid follow-up for newly diagnosed individuals.

The “Aging With HIV Cheat Sheet” provides practical, research-informed guidance for people living with HIV who are growing older — reflecting that many people with HIV now live well into middle age and beyond. It recognizes that as people with HIV age, their health needs evolve — combining general aging challenges with HIV-specific risks. 
Why aging with HIV matters more now:
•    In the U.S., more than half of people living with HIV are now aged 50 or older.

This article provides a comprehensive overview of pre-exposure prophylaxis (PrEP), a highly effective HIV prevention medication for people who are HIV-negative and at increased risk of acquiring the virus. It explains that when taken as prescribed, PrEP reduces HIV transmission risk by about 99%, making the chance of contracting HIV from someone correctly using PrEP extremely low.

This report provides an overview of high-risk HIV behaviors among women ages 18–44 in the United States, based on national surveillance data from the Behavioral Risk Factor Surveillance System (BRFSS). High-risk behaviors include injecting non-prescribed drugs, receiving treatment for a sexually transmitted infection, and exchanging sex for money or drugs within the past year. These behaviors are key indicators of HIV vulnerability and often reflect broader social and structural factors such as access to health care, substance use patterns, and economic instability.

This webinar features a presentation from the March 2024 Conference on Retroviruses and Opportunistic Infections (CROI), where Dr. Patrick Sullivan—AIDSVu Principal Scientist and Professor at Emory University—presented the oral abstract, “Association of State-Level PrEP Coverage and State-Level HIV Diagnoses, US, 2012–2021.” Using real-world data on PrEP coverage, Dr. Sullivan’s study found that states with a higher proportion of people with PrEP indications who were using PrEP experienced steeper declines in new HIV diagnoses over the past decade.

This video educates viewers on what the PrEP-to-Need Ratio is and how to properly use it to evaluate health equity.

This video walks through AIDSVu Location Profiles -- interactive, user-friendly summaries of HIV data for various locations across the U.S., including cities, counties, states, and regions. These profiles provide insights into HIV prevalence, new diagnoses, mortality, and more, helping users understand the impact of HIV in their communities.

This fact sheet discusses that navigating prescription drug access for clients can present many challenges and barriers. NASTAD is committed to developing and maintaining resources highlighting initiatives aiming to maximize affordable access to essential medicines, including programs for uninsured/underinsured individuals and cost-sharing assistance for insured individuals contending with out-of-pocket spending.

This counseling guide summarizes recommendations from the U.S. Department of Health and Human Services Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission regarding the use of antiretroviral (ARV) drugs during pregnancy or when trying to conceive. Its purpose is to support informed, shared decision-making for individuals living with HIV and their clinicians. Effective antiretroviral therapy (ART) with sustained viral suppression is the cornerstone of maternal health and prevention of perinatal HIV transmission.